Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer

Updates from the phase III KEYNOTE-522 and KEYNOTE-355 trials demonstrate the benefits of pembrolizumab added to chemotherapy in early-stage and locally advanced or metastatic triple-negative breast cancer, respectively.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963307/
https://www.ncbi.nlm.nih.gov/pubmed/35348777
http://dx.doi.org/10.1093/oncolo/oyac014
_version_ 1784677963252367360
author Jacobson, Anne
author_facet Jacobson, Anne
author_sort Jacobson, Anne
collection PubMed
description Updates from the phase III KEYNOTE-522 and KEYNOTE-355 trials demonstrate the benefits of pembrolizumab added to chemotherapy in early-stage and locally advanced or metastatic triple-negative breast cancer, respectively.
format Online
Article
Text
id pubmed-8963307
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89633072022-03-29 Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer Jacobson, Anne Oncologist Conference Perspectives: Highlights from SABCS Updates from the phase III KEYNOTE-522 and KEYNOTE-355 trials demonstrate the benefits of pembrolizumab added to chemotherapy in early-stage and locally advanced or metastatic triple-negative breast cancer, respectively. Oxford University Press 2022-03-28 /pmc/articles/PMC8963307/ /pubmed/35348777 http://dx.doi.org/10.1093/oncolo/oyac014 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Conference Perspectives: Highlights from SABCS
Jacobson, Anne
Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
title Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
title_full Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
title_fullStr Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
title_full_unstemmed Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
title_short Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
title_sort pembrolizumab improves outcomes in early-stage and locally advanced or metastatic triple-negative breast cancer
topic Conference Perspectives: Highlights from SABCS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963307/
https://www.ncbi.nlm.nih.gov/pubmed/35348777
http://dx.doi.org/10.1093/oncolo/oyac014
work_keys_str_mv AT jacobsonanne pembrolizumabimprovesoutcomesinearlystageandlocallyadvancedormetastatictriplenegativebreastcancer

Ejemplares similares